---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-251268"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:27:40.870952+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago

## Summary
- Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.
- GAAP net income $0.9M vs net loss of $6.5M in Q3 2023; adjusted EBITDA $7.6M vs $3.7M.
- Installed base expanded to 2,821 units, adding 164 units in Q3.
- Repurchased $12.1M of stock during Q3; cash and securities $277.8M.
- FY2024 revenue guidance reaffirmed at $203-210M, expecting positive operating cash flow.

## SEC filing metadata
- accession: 0001193125-24-251268
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312524251268/0001193125-24-251268-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312524251268/d825275d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-251268
- JSON: https://secwatch.observer/filing/0001193125-24-251268.json
- Plain text: https://secwatch.observer/filing/0001193125-24-251268.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.